Home > Insider Trading > Filing (0001209191-23-050033)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	Biological Products, (No Disgnostic Substances) (2836)	464099738

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856081	Shafique Virani	C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2023-09-15	18,000	$2.22	158,351	No	4	M	Direct
Class A Common Stock	Disposition	2023-09-15	18,000	$8.66	140,351	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2023-09-15	18,000	$0.00	18,000	$2.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
433,469		2030-03-03	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Remaning Holdings	Nature of Ownership
Class A Common Stock	Stock Option (Right to Buy)	$8.55		2033-02-01	212,507	Direct
Class A Common Stock	Stock Option (Right to Buy)	$11.40		2032-02-04	80,450	Direct
Class A Common Stock	Stock Option (Right to Buy)	$11.40	2022-02-04	2032-02-04	5,436	Direct

Expiration Date	Remaning Holdings	Nature of Ownership
2033-02-01	212,507	Direct
2032-02-04	80,450	Direct
2032-02-04	5,436	Direct

Footnotes

Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.